Instylla HES Hypervascular Tumor Pivotal Study

Brief description of study

This research study is being conducted to determine if a new investigational device (Instylla Hydrogel Embolic system) can be used to treat tumors which have an extensive blood supply. This means that the tumors have many blood vessels feeding them. This product will be used to close blood vessels supplying the tumor with blood to try and shrink it (embolization). Men or women for whom vascular embolization is clinically indicated and who appear to meet eligibility criteria will be consented for the study. Participants will be in this study for approximately 7 months including the 6 months following the embolization procedure. Study will involve 5 visits to Hospital of University of Pennsylvania, which includes a screening visit.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research, Hypervascular Tumors
Age: Between 22 Years - 99 Years
Gender: All

Men or women for whom vascular embolization is clinically indicated and who appear to meet eligibility criteria will be consented for the study.

Updated on 09 Mar 2024. Study ID: 849039

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).